2025
American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary
Siegal D, Tseng E, SchĂĽnemann H, Angchaisuksiri P, Cuker A, Dane K, DeSancho M, Diuguid D, Griffin D, Klok F, Lee A, Neumann I, Pai A, Righini M, Sanfilippo K, Terrell D, Akl E, Al Jabiri R, Al Jabiri Y, Barbara A, Bognanni A, Akl I, Boulos M, Brignardello-Petersen R, Chan M, Charide R, Colunga-Lozano L, Dearness K, Darzi A, Hussein H, Karam S, Kolb P, Mansour R, Morgano G, Morsi R, Muti-SchĂĽnemann G, Nadim M, Noori A, Philip B, Piggott T, Qiu Y, Benitez Y, SchĂĽnemann F, Stevens A, Solo K, Wiercioch W, Mustafa R, Nieuwlaat R. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Advances 2025, 9: 1247-1260. PMID: 39437797, PMCID: PMC11950770, DOI: 10.1182/bloodadvances.2024014219.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsCOVID-19HematologyHumansSARS-CoV-2Societies, MedicalUnited StatesVenous ThromboembolismConceptsCOVID-19-related critical illnessConditional recommendationAcute illnessHealth care professionalsAmerican Society of HematologyProphylactic-intensity anticoagulationCritical illnessEvidence-based recommendationsVenous thromboembolismRandomized controlled trialsCare professionalsPatient representativesRisk of venous thromboembolismGuideline developmentRecommendations AssessmentTherapeutic-intensity anticoagulationExecutive summaryLiving guidelinesMultidisciplinary panelIncreased risk of venous thromboembolismSystematic reviewAssessed certaintyCOVID-19-relatedControlled trialsMcMaster UniversityInitial management of patients with acquired aplastic anemia in the United States: results from a large national claims database
Stempel J, Wang R, Lee A, Zeidan A, Ma X, Podoltsev N. Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database. Annals Of Hematology 2025, 104: 2507-2515. PMID: 40102305, PMCID: PMC12052795, DOI: 10.1007/s00277-025-06307-z.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationAcquired aplastic anemiaCalcineurin inhibitorsParoxysmal nocturnal hemoglobinuriaTransfusion-dependentTriple therapyAA patientsAplastic anemiaAllogeneic hematopoietic stem cell transplantationTreated with calcineurin inhibitorsTreated with antithymocyte globulinFlow cytometryInitial management of patientsSevere AA patientsStem cell transplantationBone marrow failureImmune-mediated disordersTreatment initiation delayRetrospective cohort studyManagement of patientsDiagnosis to treatmentNational claims databaseAntithymocyte globulinSibling donorMarrow failure
2024
Trainees’ perspectives on sickle cell education: a qualitative needs assessment
Prince E, Feder K, Calhoun C, Lee A, Carroll C, Restrepo V, Van Doren L. Trainees’ perspectives on sickle cell education: a qualitative needs assessment. BMC Medical Education 2024, 24: 715. PMID: 38956512, PMCID: PMC11220977, DOI: 10.1186/s12909-024-05696-5.Peer-Reviewed Original ResearchConceptsNeeds assessmentPatient care challengesIterative thematic analysisQualitative needs assessmentCost of careComplications of SCDBackgroundSickle cell diseaseCare challengesHealthcare biasesSpecific educationThematic analysisMedical traineesFocus groupsClinical careTrainees' attitudesQualitative interviewsLack of national standardsLongitudinal exposureClinical teachingUnited StatesExpert cliniciansSubspecialty trainingTraineesCareHealthcare
2023
Burnout in U.S. hematologists and oncologists: impact of compensation models and advanced practice provider support
Lee A, Masselink LE, De Castro LM, Marshall AL, Connell NT, Dent GA, Fritz J, Homer M, Lucas TL, Naik RP, Nelson M, O'Connell C, Rajasekhar A, Reynolds R, Sharma D, Smith M, Weeks LD, Erikson CE. Burnout in U.S. hematologists and oncologists: impact of compensation models and advanced practice provider support. Blood Advances 2023, 7: 3058-3068. PMID: 35476017, PMCID: PMC10331414, DOI: 10.1182/bloodadvances.2021006140.Peer-Reviewed Original ResearchMeSH KeywordsBurnout, ProfessionalFemaleHumansJob SatisfactionMaleOncologistsPhysiciansSurveys and QuestionnairesUnited StatesConceptsCommunity physiciansProvider supportMultivariate logistic regression modelOverall survey response rateClinical support staffCommunity practiceLogistic regression modelsHigh burnoutUS hematologistsSurvey response rateComplete responseFemale genderAMA MasterfileResponse rateSignificant associationHematologistsOncologistsFinal analysisPhysiciansLarge-scale studiesProvider UtilizationPractice surveyAmerican SocietyOne-thirdPhysician compensation
2020
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2020, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2019
Trends and factors affecting the US adult hematology workforce: a mixed methods study
Sharma D, Wallace N, Levinsohn EA, Marshall AL, Kayoumi K, Madero J, Homer M, Reynolds R, Hafler J, Podoltsev NA, Lee AI. Trends and factors affecting the US adult hematology workforce: a mixed methods study. Blood Advances 2019, 3: 3550-3561. PMID: 31738829, PMCID: PMC6880914, DOI: 10.1182/bloodadvances.2019000307.Peer-Reviewed Original ResearchConceptsHematology/oncology fellowsBenign hematologyOncology fellowsASH annual meetingClinical care modelsMixed-methods studyMajority of fellowsAdult hematologistsSeparate focus groupsCare modelClinical careMethods studyFellowship program directorsFocus group participantsHematologyMore fellowsFellowship trainingSingle training programOncologyGroup participantsLongitudinal studyAmerican SocietyNational studyOncology facultyFocus group discussions
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply